Dyne Therapeutics (DYN) Cash from Investing Activities (2019 - 2026)

Dyne Therapeutics (DYN) has 8 years of Cash from Investing Activities data on file, last reported at -$2.4 million in Q1 2026.

• On a quarterly basis, Cash from Investing Activities fell 264.06% year-over-year to -$2.4 million in Q1 2026; TTM through Mar 2026 was -$32.6 million, a 43.11% decrease from a year earlier, with the FY2025 full-year figure at -$28.8 million, up 85.91% from the prior year.
• Cash from Investing Activities for Q1 2026 stood at -$2.4 million, down from $982000.0 in the prior quarter.
• Over the last five years, Cash from Investing Activities for DYN reached as high as $51.7 million in Q3 2022 and fell as low as -$179.8 million in Q1 2024.
• Historically, Cash from Investing Activities has averaged -$3.8 million across 5 years, with a median of $6.8 million in 2025.
• Across the five-year window, Cash from Investing Activities soared 8285.96% in 2022 and slumped 764.54% in 2024, its largest moves.
• Year by year, Cash from Investing Activities stood at $19.2 million in 2022, then jumped by 36.18% to $26.2 million in 2023, then tumbled by 161.12% to -$16.0 million in 2024, then soared by 106.13% to $982000.0 in 2025, then plunged by 343.58% to -$2.4 million in 2026.
• Per Business Quant data, the three most recent Cash from Investing Activities figures were -$2.4 million in Q1 2026, $982000.0 in Q4 2025, and -$38.0 million in Q3 2025.